Become a logicalchat Member

Latest Post

Conquering the Mountain: Avalanche vs. Snowflake Debt Repayment in Canada

For Canadians wrestling with debt, the path to financial freedom can feel daunting. But fear not, our brave loonie-wielding friends! Two effective debt repayment...

Your story starts here. Sign up and let's connect in ways that truly matter!

HomeUncategorizedAfter-Market: Klaviyo, Goldman Sachs gains , Hillevax down . Sep-20

After-Market: Klaviyo, Goldman Sachs gains , Hillevax down . Sep-20

After-Market:

After-Market

After-Market active stocks

Gainers

  • Nano Dimension Ltd (NASDAQ:NNDM) 5% UP; got Israeli court clearance to extend its previously announced share repurchase scheme, which was approved by the Israeli court in August 2022, through October 12, 2023.
  • Steelcase (NYSE:SCS) is up 4% after reporting Q2 earnings per share of $0.31, $0.11 higher than the analyst expectation of $0.20. Revenue for the quarter was $854.6 million, compared to the consensus expectation of $829.17 million. Steelcase expects FY2024 earnings per share of $0.80-$0.90, compared to the consensus of $0.67.

Losers

  • Hillevax Inc (NASDAQ:HLVX) 6% LOWER; said that it intends to offer and sell $100.0 million of its common stock in an underwritten public offering, subject to market and other conditions.
  • Permian Resources Corp (NYSE:PR) 2% LOWER; certain affiliates of NGP Energy Capital Management L.L.C. have begun an underwritten public offering of an aggregate of 20,300,000 shares of its Class A Common Stock, par value $0.0001 per share.
  • Instacart (Maplebear Inc.) (NASDAQ:CART) is down 1% after gaining 12% in its initial public offering. Needham & Company initiated coverage with a Hold rating following the close.

MARKET MOVERS 

IBM
International Business Machines Corp

146.52
0.986%  

INTC
Intel Corp

36.34
4.343%

   

AAPL
Apple Inc
179.07
0.618%    

DIS
Walt Disney Co

81.94
3.623%    

HON
Honeywell International Inc

195.35
0.458%      

UNH
UnitedHealth Group Inc

480.66
1.111%    

AMGN
Amgen Inc

264.31
0.441%   
NKE
Nike Inc
94.62
0.932%     

CRM
Salesforce Inc

215.7
0.326%

DOW
Dow Inc
52.9
0.899%  

Midday-Market movers

GAINERS

Klaviyo Inc (NYSE:KVYO) shares rose 15% on their first day of trading following an initial public offering that valued the company at roughly $9 billion.

Goldman Sachs (NYSE:GS) climbed 0.3% after the investment bank’s asset management division secured more than $15 billion for funds that allow investors to make secondary investments in existing private equity ventures.

The stock of Coty (NYSE:COTY) increased 4.8% after the beauty company improved its year core sales projection due to greater pricing and strong demand for its premium perfumes.

Dollar General (NYSE:DG) stock rose 0.3% after JPMorgan downgraded the budget retailer to ‘underweight’ from ‘neutral,’ citing considerable financial stress among its core low-end consumer.

LOSERS

  • Instacart (NASDAQ:CART) stock slumped 5.2%, wiping out some of the 12% gains made by the online grocery delivery business on its first day of trading following a successful IPO.
  • Chewy (NYSE:CHWY) stock slumped 4.3% after Oppenheimer downgraded the pet food retailer to ‘perform’ from ‘outperform,’ predicting that the “challenging backdrop” will last for at least a few more quarters.
  • Apple’s (NASDAQ:AAPL) stock dipped 0.9% after unions at the tech giant’s French stores called for a strike on Friday and Saturday ahead of the iPhone 15 launch, demanding more pay and improved working conditions.
  • General Mills (NYSE:GIS) stock declined 0.2% after the food processing company topped analysts’ forecasts for quarterly revenue, thanks to price increases on breakfast cereals, snack bars, and pet food products that helped soften the impact of sluggish demand.

INSIDER TRADES

The CEO of Planet Labs purchases $270,000 in stock.
Planet Labs (PL) Co-Founder and CEO William Spencer Marshall declared the purchase of 100,000 common shares on 09/19/23 at $2.6984 in a Form 4 filing after the close.

The buying price was $269,840.

Marshall now owns 1,405,356 shares after the most recent transaction.

RXO Director Szlosek purchases $100,000 in stock.

RXO (RXO) Director Thomas Szlosek announced the purchase of 11,186 common shares on 09/15/23 at $17.92 in a Form 4 filing after the close.
The buying price was $200,453.12.
Following the latest acquisition, Szlosek now owns a total of 13,034 common shares.

The Hain Celestial Supply Chain Officer purchases $300,000 in stock.
Steven Golliher, Global Ch Supply Chain Officer at Hain Celestial (HAIN), declared the acquisition of 30,000 common shares on 9/15/23 at $10.1601 in a Form 4 filing after the closing.
The purchasing price was $304,803.
Following the latest acquisition, Golliher now owns a total of 36,274 common shares.

The CEO of Hain Celestial purchases $100,000 in stock.

Wendy Davidson, President and CEO of Hain Celestial (HAIN), declared the acquisition of 10,000 common shares on 09/15/23 at $9.9998 in a Form 4 filing after the close.
The buying price was $100,000.
Following the last acquisition, Davidson now owns 16,636 total shares.

Earnings Calendar

Wednesday, September 20 

  • FedEx Corp. (FDX), General Mills (GIS), and KB Home (KBH)  

Thursday, September 21  

Darden Restaurants (DRI) and FactSet Research Systems Inc. (FDS)

  • Workhorse Group Inc. (Nasdaq: WKHS) 32% HIGHER; Workhorse Group Inc. (Nasdaq: WKHS) announced that it has achieved IRS clearance as a qualified manufacturer for the Commercial Clean Vehicle Credit, as specified in Internal Revenue Code Section 30D(d)(3). With this approval, Workhorse clients can receive up to a $40,000 credit for all Workhorse vehicle deliveries in 2023 and beyond.
  • Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) 29% HIGHER; Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) reported that it has reached an agreement with the Food and Drug Administration (FDA) on the global Phase 2 pivotal study of RP-A501 for Danon Disease. Danon Disease is a deadly hereditary cardiomyopathy that kills the majority of male patients at the age of 20 and the majority of female patients at the age of 40, and for which there are no authorized curative or disease-modifying medications. In the United States and Europe, the condition affects an estimated 15,000 to 30,000 people.

After-Market: After-Market: After-Market: After-Market: After-Market: After-Market: After-Market: After-Market: After-Market: After-Market:

Related Post